2023 年第 3 期 第 18 卷

新型镇静药物瑞马唑仑的研究进

Research progress of new sedative drug remimazolam

作者：窦豆栗亚茹王璐冯艺姜陆洋

英文作者：Dou Dou Li Yaru Wang Lu Feng Yi Jiang Luyang

单位：

英文单位：Department of Anesthesiology Peking University People′s Hospital Beijng 100044 China

关键词：瑞马唑仑；镇静药；苯二氮类

英文关键词：Remimazolam;Sedative;Benzodiazepine

• 摘要：

• 瑞马唑仑是一种新型苯二氮类镇静药物，通过作用于γ-氨基丁酸A型受体可产生同咪达唑仑类似的镇静催眠作用，其代谢通过血浆组织酯酶而不依赖肝肾，长时间输注无蓄积，对呼吸及循环功能影响轻微，在临床镇静诊疗应用中具有一定优势，已获批用于临床胃肠镜诊疗的镇静。有关其在临床镇静和全身麻醉方面有效性和安全性的试验正逐步开展，未来瑞马唑仑在临床中更为广泛的应用仍有待进一步探究。本文通过检索瑞马唑仑研究相关文献，就其作用机制、药动学、临床应用和安全性作一综述。

• Remimazolam is a novel benzodiazepine. Like midazolam, it acts on γ-aminobutyric acid A receptors to induce sedation. Remimazolam is hydrolyzed by plasma tissue esterases rather than liver and renal metabolism. The concentration of remimazolam might not accumulate after long term infusion. The new sedative has a mild depression effects on respiratory and circulatory function, showing advantages in clinical sedation application. It is approved to provide procedural sedation for upper gastrointestinal endoscopy and colonoscopy. Several trials have been proceeding in terms of the safety and efficiency of remimazolam for clinical sedation and general anesthesia. Further studies are needed to explore more clinical application of remimazolam. The action mechanism, pharmacokinetics, clinical application and safety of remimazolam are introduced in this paper by searching references on remimazolam.